

Pierre Johansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5404924/publications.pdf>

Version: 2024-02-01

26
papers

335
citations

758635

12
h-index

887659

17
g-index

26
all docs

26
docs citations

26
times ranked

262
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 611-621.	2.2	35
2	Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations. <i>PLoS ONE</i> , 2014, 9, e110235.	1.1	34
3	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). <i>Pharmacoeconomics</i> , 2017, 35, 375-396.	1.7	24
4	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019, 10, 1297-1317.	1.2	23
5	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022, 4, 100525.	2.6	23
6	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. <i>Pharmacoeconomics - Open</i> , 2019, 3, 537-550.	0.9	20
7	Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. <i>Value in Health Regional Issues</i> , 2015, 8, 8-19.	0.5	17
8	Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. <i>Pharmacoeconomics</i> , 2020, 38, 953-969.	1.7	16
9	The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. <i>Pharmacoeconomics</i> , 2022, 40, 751-776.	1.7	16
10	Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20% years of linked national registry data in Sweden. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1586-1597.	2.2	15
11	Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. <i>Advances in Therapy</i> , 2020, 37, 2427-2441.	1.3	15
12	Cost-Effectiveness Analysis of Canagliflozin 300mg Versus Dapagliflozin 10mg Added to Metformin in Patients with Type 2 Diabetes in the United States. <i>Diabetes Therapy</i> , 2018, 9, 565-581.	1.2	13
13	Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. <i>Pharmacoeconomics</i> , 2020, 38, 485-497.	1.7	12
14	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4593-e4604.	1.8	12
15	External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. <i>Pharmacoeconomics</i> , 2020, 38, 1123-1133.	1.7	11
16	A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00259.	1.0	8
17	Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2016, 23, e151-68.	1.4	8
18	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. <i>Advances in Therapy</i> , 2019, 36, 1190-1199.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, .	0.3	7
20	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. <i>Advances in Therapy</i> , 2020, 37, 1248-1259.	1.3	5
21	The prevalence of comorbidities in Danish patients with obesity – A Danish register-based study based on data from 2002 to 2018. <i>Clinical Obesity</i> , 2022, 12, .	1.1	5
22	Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada. <i>Diabetes</i> , 2018, 67, .	0.3	4
23	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. <i>Value in Health Regional Issues</i> , 2019, 18, 65-73.	0.5	3
24	Once-Weekly Semaglutide Provides Better Value for Money Than a Broad Range of Other Type 2 Diabetes Treatments in Canada: A Relative Cost of Control Analysis. <i>Canadian Journal of Diabetes</i> , 2018, 42, S41.	0.4	2
25	Authors'™ reply to Comment on –External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions–. <i>Pharmacoeconomics</i> , 2021, 39, 137-138.	1.7	0
26	The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, , 1-11.	0.7	0